Drug Profile
Research programme: Burkholderia infections vaccine - Bavarian Nordic
Latest Information Update: 28 Mar 2023
Price :
$50
*
At a glance
- Originator Bavarian Nordic
- Class Bacterial vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Burkholderia infections
Most Recent Events
- 28 Mar 2023 Discontinued - Preclinical for Burkholderia infections in Denmark (Parenteral)
- 28 Jul 2018 No recent reports of development identified for preclinical development in Burkholderia infections in Denmark (Parenteral)
- 18 Apr 2017 Bavarian Nordic in-licenses EB66® cell-line technology from Valneva